Sugi Predict

Sugi Predict / Compounds / SCHEMBL25834108

SCHEMBL25834108

SCHEMBL25834108

Cc1cccc2c(OCc3ccccc3)cc(N(C[C@@H]3CO3)C(=O)OC(C)(C)C)c(Br)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.35
▸ KLK7 P49862 2/20 0.34
▸ PTGER4 P35408 2/20 0.34
▸ PTGER3 P43115 2/20 0.34
▸ PTGER2 P43116 2/20 0.34
▸ EDNRA P25101 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ FFAR1 O14842 1/20 0.34
▸ BCHE P06276 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ MAOB P27338 2/20 0.33
▸ PTGER1 P34995 2/20 0.33
▸ KLK5 Q9Y337 1/20 0.33
▸ LTB4R Q15722 1/20 0.33
▸ LTB4R2 Q9NPC1 1/20 0.33
▸ THRA P10827 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ MRGPRX4 Q96LA9 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ RXRB P28702 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18883282 1.00 FFAR4 (0.35) FFAR4KLK7PTGER4PTGER3PTGER2
SCHEMBL17318675 0.89 FFAR4 (0.38) FFAR4PTGER4PTGER3PTGER2EDNRA
SCHEMBL19493270 0.87 TP53 (0.32) BCHECNR2
SCHEMBL29424475 0.84 KLK7 (0.35) FFAR4KLK7L3MBTL1FFAR1MAOB
SCHEMBL29424477 0.84 KLK7 (0.35) FFAR4KLK7L3MBTL1FFAR1MAOB
SCHEMBL1902732 0.84 KLK7 (0.35) FFAR4KLK7L3MBTL1FFAR1MAOB
SCHEMBL20434247 0.79 L3MBTL1 (0.33) FFAR4KLK7PTGER4PTGER3PTGER2
SCHEMBL18406736 0.78 L3MBTL1 (0.33) FFAR4KLK7PTGER4PTGER3PTGER2
SCHEMBL18406660 0.78 L3MBTL1 (0.33) FFAR4KLK7PTGER4PTGER3PTGER2
SCHEMBL18406744 0.77 TLR9 (0.32) FFAR4KLK7PTGER4PTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024178155-A1 TRANS-CYCLOOCTENE CONJUGATES TAMBO, INC. (US) 2024-08-29 — — WO disclosed
US-20230272084-A1 B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES MACROGENICS, INC. 2023-08-31 — — US disclosed
US-20230272084-A1 B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES MACROGENICS, INC. 2023-08-31 — — US disclosed
WO-2023154784-A1 METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE MACROGENICS, INC. (US) 2023-08-17 — — WO disclosed
US-20230226206-A1 METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION MACROGENICS, INC. 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230272084-A1 B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES CD274, CD2, CD22 FFAR4 1691/4885KLK7 1752/4885PTGER4 3231/4885
US-20230226206-A1 METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION CD274, PDCD1, H1-3 FFAR4 3363/4885KLK7 1538/4885PTGER4 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.